We seek to overcome the major challenges in drug discovery and development with our in silico drug design platform.

We focus on what we do best—designing drugs for partners and improving our drug design technology. Our business model is simple: we are rewarded only if our compounds work and add value to our partner’s pipeline.

Change the design process. Numerate’s in silico drug design technology makes the drug design process more efficient and less unpredictable. Our novel approach to chemical design reduces the timelines, costs, and attrition rates of traditional drug discovery. Our technology combines advances in computer science and statistics with medicinal chemistry, enabling us to predict potential causes of drug success and failure at design-time, and to identify the best compounds based on these predictions.

Partner with biology. By combining our unique design capabilities with the biological and medical knowledge of our partners, we reduce the cost of generating valuable hits, leads, and drug candidates as well as increase their value by addressing at the outset the causes of downstream attrition.

Extend the platform. Numerate’s drug design technology results from 10 years of intensive development in both academic and commercial environments and represents a $30 million investment. Numerate continuously extends the platform’s capability to predict more causes of drug success and failure, focusing currently on pharmacokinetics and toxicity.